Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes
An international cohort of 2,052 NSCLC patients with leptomeningeal disease shows rising prevalence and improved survival in the modern treatment era. CNS‑penetrant tyrosine kinase inhibitors and immune checkpoint inhibitors are key drivers of delayed onset and longer leptomeningeal survival.